Eftrenonacog Alfa

艾诺凝血素α

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEftrenonacog Alfa
Drug Alias Name依凝血素-9αEftrenonacog αeftrenonacog alfaEftrenonacog Alphaeftrenonacogum alfa +[14] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCoagulation factor X stimulantsBlood coagulation pathway activation
TargetsCoagulation factor X
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsHemophilia B
Approved Indications in ChinaHemophilia B
Original Approved Country/TerritoryUnited States
Original Approved Date2014/03/28
Country/TerritoryBelgiumCanadaUnited States +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSobiBiogen IncBioverativ Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Idec Research LtdBiogen IncSwedish Orphan Biovitrum Ab (Publ) +[6] 
Inactive CompaniesBioverativ, A Sanofi CompanySyntonix Pharmaceuticals Inc
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeB02BD04
Related LinksDrugBankKEGG